Next Phase Newsletter

An investment firm headquarters in China with offices in the US focuses on early-stage investments in life science and healthcare sectors. The firm typically engages in pre-A to series B financing rounds, with initial investment sizes ranges from $500k to $8M, and potential for follow-on investments. The firm looks for opportunities mostly in Europe, and in the US and UK as well. The firm is open to both leading and co-investing. 
 
The firm is interested in therapeutics, medical devices and diagnostics. The firm is open to looking at digital health, AI -related companies but has not invested in one yet. The firm is opportunistic in terms of subsectors and indications. Some areas of interest include immunology, immuno-oncology, CNS disorders and kidney-related diseases. For therapeutics, the firm is open to looking at companies from phase I to beyond, particularly those with proof of concepts or clinical data validating their technologies. For medical devices and diagnostics, the firm tends to look for more mature companies, with product or prototype ready and as well as plans for regulatory approvals. 
 
The firm does not have specific requirements for a company’s management team but prefers to work with founding teams that have entrepreneurial experiences previously. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

The firm is a Private Equity firm that was founded in 2001 and based in Paris, France. The firm controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.  For in-licensing opportunities the firm is willing to look globally. 
 
The firm Is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development. 
 
The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A single family office is an active investor in early-stage companies. The firm is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America. 
 
The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating  loss of senses. 
 
The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm headquartered in China currently holds ¥3B in assets under management. Historically, the firm focused on investing only in China. However, the current fund of $300M USD is focused on opportunities in the United States. The firm invests in early-stage life science ventures from Seed to Series B. Typical initial size of investment ranges from $100k-5M USD. 
 
The firm will consider cost-effective therapeutics and diagnostics that reach urgent and unmet clinical needs. Within therapeutics, the firm is interested in cell & gene therapy, gene editing, and organoids, and looks at pre-clinical to Phase III. Within diagnostics, the firm is open to all types of technologies and phases of development. 

With an overarching focus on the aging population, the firm is interested in technologies that can improve the quality and longevity of life. The main indication areas of interest are neurological pathways, CNS, and chronic and acute pain management. 
 
The firm does not have any requirements of the management team. Further down the road, the firm is able to support companies that are interested in entering the China market. However, having a China angle is not necessary for investment. The firm intends to act as a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm based in Europe with offices in the US traditionally invests in agtech but is also currently interested in the intersections between bioeconomy and traditional life sciences. The firm is currently investing out of its $400M fund in Seed to Series B companies with typical check sizes ranging from $1-15M USD. The firm is opportunistic in geography but has preference in the EU and US. The firm can act as a lead investor or syndicate. 
 
In terms of life sciences, the firm is interested in R&D enabling software, non-software enabling technologies, and medical foods whether that is asset- or software-oriented. 
 
The firm does not require to take a board seat and does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

A European focused venture capital firm founded in 2015 with partners based in Europe and US. The firm has a current fund which is actively investing in Spain, Portugal, the UK, and Ireland. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in series A & series B financings as a Lead or co-Lead with investments ranging from €3 million to €8 million over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over next 4 years. The firm will only invest in private companies. 
 
The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is strongly interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platform and analytics areas, such as big data-driven technologies on complex medical research. 
 
The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital arm of a global pharmaceutical company with a market cap exceeding $8 million, is actively investing in the early-stage healthcare sector. The firm focuses on seed-stage opportunities, with the initial investment range broadly, spanning up to several million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly financial driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.